Ubrelvy (ubrogepant) is an oral medication approved for the acute treatment of migraine with or without aura in adults [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [1].
How Does Ubrelvy Work for Migraine?
Ubrelvy functions by blocking the action of CGRP, a molecule that plays a role in migraine pain [1][2]. By inhibiting CGRP from binding to its receptors, Ubrelvy helps to reduce the inflammation and vasodilation associated with migraine attacks [1].
What Dosages of Ubrelvy Are Available?
Ubrelvy is available in two dosage strengths: 50 mg and 100 mg [1]. The recommended starting dose is typically 50 mg, with an option to take a second 50 mg dose at least two hours later if needed [1]. For patients who do not achieve pain freedom or satisfactory pain reduction with the 50 mg dose, the 100 mg dose can be considered, also with the option for a second 100 mg dose at least two hours later [1].
When Was Ubrelvy Approved and By Whom?
Ubrelvy was approved by the U.S. Food and Drug Administration (FDA) on December 23, 2019 [1]. It is manufactured by AbbVie Inc. [3].
What Are the Potential Side Effects of Ubrelvy?
Common side effects associated with Ubrelvy include nausea, fatigue, and dry mouth [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How Does Ubrelvy Compare to Other Migraine Treatments?
Ubrelvy represents a different class of acute migraine treatment compared to older medications like triptans, which also target serotonin receptors [2]. As a CGRP receptor antagonist, Ubrelvy offers an alternative mechanism of action for individuals who may not respond well to or tolerate triptans [2]. Other CGRP inhibitors are available as injectables for migraine prevention, but Ubrelvy is an oral option for acute treatment [2].
What Are the Patent and Exclusivity Details for Ubrelvy?
Information regarding the specific patents and exclusivity periods for Ubrelvy can be found on drug patent tracking websites [4]. These resources track patent filings, expiration dates, and any legal challenges that may affect market exclusivity for pharmaceuticals like Ubrelvy [4]. DrugPatentWatch.com is a resource that monitors drug patents and can provide details on such information [4].